Get the Stockscreener App
22.37
1.11%
-0.25
10 X Genomics Inc stock is traded at $22.37, with a volume of 1.97M.
It is down -1.11% in the last 24 hours and up +17.37% over the past month.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
See More
Previous Close:
$22.62
Open:
$22.61
24h Volume:
1.97M
Relative Volume:
0.81
Market Cap:
$2.86B
Revenue:
$631.73M
Net Income/Loss:
$-239.78M
P/E Ratio:
-11.07
EPS:
-2.02
Net Cash Flow:
$-33.45M
1W Performance:
+13.78%
1M Performance:
+17.37%
6M Performance:
+64.85%
1Y Performance:
+112.64%
1-Day Range:
$22.20
$23.09
1-Week Range:
$19.66
$23.30
52-Week Range:
$6.78
$23.56
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, TEM, BTSG, HQY, WAY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
22.37 | 2.89B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
188.48 | 30.56B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
51.29 | 9.19B | 1.27B | -245.03M | -245.36M | -1.4071 |
|
BTSG
Brightspring Health Services Inc
|
41.96 | 7.33B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
81.15 | 6.87B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
26.93 | 5.09B | 906.14M | -52.62M | 89.62M | -0.3621 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-11-25 | Initiated | Piper Sandler | Neutral |
| Feb-13-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-22-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-10-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Hold |
| May-01-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
10x Genomics (TXG) CEO sells shares and makes stock gift - Stock Titan
10x Genomics $TXG Position Lifted by Vanguard Group Inc. - MarketBeat
10X Genomics Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Breaking Down 10x Genomics: 11 Analysts Share Their Views - Sahm
Commit To Buy 10x Genomics At $15, Earn 20.6% Annualized Using Options - Nasdaq
TXG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
10x Genomics, Inc. (TXG) Stock Analysis: A Closer Look at the Healthcare Innovator’s Growth Potential and Analyst Ratings - DirectorsTalk Interviews
Stifel Nicolaus Boosts 10x Genomics Price Target to $25 - National Today
Major RSU grant to 10x Genomics (TXG) CEO Serge Saxonov - Stock Titan
88,816 RSUs awarded to 10x Genomics (TXG) director Hindson - Stock Titan
10x Genomics (TXG) CFO granted 106,579 RSUs in new equity award - Stock Titan
TXG affiliate files Form 144: proposed Class A Common sale (NASDAQ: TXG) - Stock Titan
10X Genomics Hits Day High with Strong 12.56% Intraday Surge - Markets Mojo
Is It Time To Reassess 10x Genomics (TXG) After Its 1 Year Share Price Surge - Yahoo Finance
10x Genomics (NASDAQ:TXG) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Is 10x Genomics Inc.’s ROIC above industry averageTrade Performance Summary & AI Driven Price Forecasts - mfd.ru
Insider Sell: Sarah Teichmann Sells Shares of 10x Genomics Inc (TXG) - GuruFocus
Director at 10x Genomics (TXG) sells 7,579 shares under 10b5-1 plan - Stock Titan
10x Genomics (TXG) Price Target Increased by 10.28% to 20.33 - Nasdaq
10x Genomics (NASDAQ:TXG) CEO Serge Saxonov Sells 9,632 Shares of Stock - MarketBeat
10x Genomics (TXG) CEO sells 9,632 shares to cover RSU tax - Stock Titan
[Form 4] 10x Genomics, Inc. Insider Trading Activity - Stock Titan
10x Genomics (TXG) officer sells 7,826 shares to cover RSU tax - Stock Titan
10x Genomics, Inc. (TXG) Stock Analysis: Navigating Growth Potential In Health Information Services - DirectorsTalk Interviews
Vestmark Advisory Solutions Inc. Sells 340,854 Shares of 10x Genomics $TXG - MarketBeat
Insider sale filing for TXG (NASDAQ: TXG) lists 8,301 shares on 02/23/2026 - Stock Titan
TXG (NASDAQ: TXG) insider sale notice: 25,784 RSU shares listed for sale - Stock Titan
Issuer insider sale notice — 23,767 shares (NASDAQ: TXG) - Stock Titan
Is 10x Genomics Inc. (1KJ) stock positioned for secular growthRecession Risk & Expert Curated Trade Ideas - mfd.ru
TXG: UBS Raises Price Target for 10x Genomics to $20 | TXG Stock News - GuruFocus
10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference - BioSpace
5 Must-Read Analyst Questions From 10x Genomics's Q4 Earnings Call - Finviz
GSA Capital Partners LLP Buys 106,167 Shares of 10x Genomics $TXG - MarketBeat
162,202 Shares in 10x Genomics $TXG Bought by Principal Financial Group Inc. - MarketBeat
10x Genomics Stock Climbs as Analysts Signal Growth Prospects - StocksToTrade
10x Genomics’ Growth Prospects Brightened by Strategic Advances - timothysykes.com
10x Genomics Cancer Alliances Test AI Ambitions Against Mixed Share Performance - Yahoo Finance
10x Genomics Sees Bullish Momentum Following Revenue Projections and Price Target Upgrades - StocksToTrade
10x Genomics Sees Bullish Momentum with Raised Price Targets - timothysykes.com
Is 10x Genomics Inc. still a buy after recent gains2025 Biggest Moves & AI Forecast Swing Trade Picks - mfd.ru
Decoding 10x Genomics Inc (TXG): A Strategic SWOT Insight - GuruFocus
Earnings Call Summary | 10x Genomics(TXG.US) Q4 2025 Earnings Conference - 富途牛牛
Expert Outlook: 10x Genomics Through The Eyes Of 10 Analysts - Benzinga
10X Genomics stock price target raised to $22 from $20 at Canaccord Genuity - Investing.com UK
Why Is 10x Genomics (TXG) Stock Soaring Today - Finviz
10X Genomics stock price target raised to $22 from $20 at Canaccord Genuity By Investing.com - Investing.com India
10x Genomics (NASDAQ:TXG) Shares Gap Up on Earnings Beat - MarketBeat
10x Genomics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
10x Genomics, Inc. (NASDAQ:TXG) Q4 2025 Earnings Call Transcript - Insider Monkey
10x Genomics Q4 Earnings Call Highlights - MarketBeat
10x Genomics, Inc. SEC 10-K Report - TradingView
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.23%
1.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):